Discover the Frontier Pharma Chronic Obstructive Pulmonary Disease (COPD) – Identifying and Commercializing First-in-Class Innovation


“The Report Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) – Identifying and Commercializing First-in-Class Innovation provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression.

The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. In comparison to other indications, this is relatively low; however, there are some promising trends within COPD product development. The Preclinical Phase of development is the most active in terms of first-in-class products. This diminishes throughout clinical development, with only two such products being present in Phase III. However, if either of these products is approved, they would represent the first, first-in-class products to be approved for COPD since roflumilast, which was approved in 2011 by the FDA and in 2010 in the EU. Roflumilast was the first novel therapy for COPD in almost 20 years, which demonstrates the infrequency at which first-in-class products enter the COPD market. So to have two first-in-class products in Phase III and six in Phase II is a promising sign.

Download Sample copy of this Report at :


The COPD market has benefited from notable additions in recent years.

  • Which classes of drug dominate the market?

  • What additional benefits have newly approved therapies brought to market?

  • How do the leading marketed therapies compare clinically?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD and novel, first-in-class therapies.

  • Which molecular targets appear most frequently in the pipeline?

  • To what degree is the pipeline penetrated by first-in-class innovation?

  • Which target families consist of the most first-in-class products?

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 4

2.1 Unmet Needs Remain in COPD Market 4

2.2 First-in-Class Innovation Beginning to Emerge in COPD 4

2.3 COPD Lags Behind Asthma in First-in-Class Innovation 4

3 The Case for Innovation in COPD 5

3.1 Growing Number of Opportunities for Biologic Products 6

3.2 Diversification of Molecular Targets 6

3.3 Innovative First-in-Class Product Developments Remain Attractive 6

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7

3.5 Sustained Innovation 7

3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9

4.1 Disease Overview 9

4.1.1 Epidemiology 9

4.1.2 Symptoms 9

4.1.3 Etiology 9

4.1.4 Pathophysiology 9

4.1.5 Diagnosis 11

4.1.6 Assessment of Disease Severity 11

4.1.7 Treatment 12

4.1.8 Treatment Algorithm 14

4.2 Overview of Marketed Products 14

4.2.1 Molecule Type and Target Analysis 15

4.2.2 Quick Relief Medication 15

4.2.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy 15

4.2.4 Bronchodilator Monotherapy 16

4.2.5 Bronchodilator Combination Therapy 17

4.2.6 Alternative Therapy 17

4.2.7 Conclusion 17

4.2.8 Unmet Needs 18

5 Assessment of Pipeline Product Innovation 19

5.1 Molecular Target Analysis 21

5.2 Comparative Distribution of Programs between COPD Market and Pipeline by Therapeutic Target Family 26

5.3 First-In-Class Pipeline Programs Targeting Novel Molecular Targets 26

6 Signaling Pathways, Disease Causation and Innovation Alignment 30

6.1 The Complexity of Signaling Networks in COPD 30

6.2 Signaling Pathways and First-in-Class Molecular Target Integration 30

6.3 First-in-Class Target Matrix Assessment 31

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074